Clinical Trials

FDA Drug Approvals Show Progress in Gene Therapy and Safety
Research & Development FDA Drug Approvals Show Progress in Gene Therapy and Safety

The landscape of medical treatment and drug development is experiencing a new dawn as the U.S. Food and Drug Administration (FDA) plays a pivotal role in ushering in an era where the once unimaginable becomes reality. With a discerning eye on cutting-edge therapies, especially in gene therapy and

Is PLX-R18 the Future of Nuclear Radiation Therapy?
Research & Development Is PLX-R18 the Future of Nuclear Radiation Therapy?

In the rapidly advancing field of nuclear radiation therapy, a groundbreaking treatment is emerging, promising to redefine the landscape of medical response to nuclear events. Financed by the backing of a weighty $4.2 million agreement with the National Institute of Allergy and Infectious Diseases

Is the DEA Blocking Progress in Cannabis Medical Research?
Research & Development Is the DEA Blocking Progress in Cannabis Medical Research?

As the field of medical research forges ahead, certain pioneering companies are facing a formidable hurdle. MMJ BioPharma Labs and MMJ International Holdings, at the forefront of developing cannabis-based pharmaceuticals, find themselves entangled in a problematic scenario with the Drug Enforcement

Asthma Treatments Expand with 90+ Pipelines by Global Firms
Research & Development Asthma Treatments Expand with 90+ Pipelines by Global Firms

As we witness a demanding push for the development of innovative asthma treatments, over 80 key companies globally have embarked on an ambitious journey. This initiative aims to create a robust arsenal of more than 90 therapeutic approaches, targeting a condition that continues to affect the

Colorectal Cancer Pipeline 2024: Innovations in Treatment
Research & Development Colorectal Cancer Pipeline 2024: Innovations in Treatment

As the battle against cancer continues, one particular area showing remarkable strides is colorectal cancer research and treatment. With over 195 key players in the industry, a testament to the competitive yet collaborative nature of the field, advancements are moving at an incredible pace. From

S&P 500 Surge Signals Bright End; Biopharma Stocks Shine
Research & Development S&P 500 Surge Signals Bright End; Biopharma Stocks Shine

The financial markets have recently witnessed a significant uptick, particularly focusing on the robust performance of the S&P 500 index. With a history of early gains often translating into positive year-end outcomes, the current rise of over 10% within the first 100 trading days has set a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later